MD, PhD
Line Aas Mortensen
Department of Nephrology, Odense University Hospital
| Projekt styring | ||
| Projekt status | Open | |
| Data indsamlingsdatoer | ||
| Start | 01.01.2025 | |
| Slut | 01.01.2035 | |
SPIREN-EXT - long term follow-up from the SPIREN trial
Short summary
Long term follow-up of patients who previously participated in the SPIREN trial. The purpose of the present trial is to evaluate long-term renal and cardiovascular outcomes as well as side effects and feasibility of using spironolactone in renal transplant patients outside a clinical trial setting.
Rationale
End stage kidney disease (ESKD) is an increasing health problem, which affects more than two million people worldwide (1). Renal transplantation is the preferred treatment of ESKD and improves mortality, morbidity, and quality of life compared with any form of dialysis. Long-term allograft survival remains a challenge in renal transplantation. The mineralocorticoid hormone aldosterone contributes to renal fibrosis through increased inflammation, endothelial dysfunction and oxidative stress. The SPIREN trial tested the effect of the mineralocorticoid antagonist spironolactone for 3 years in kidney transplant patients and found no difference in the slope of eGFR.
Description of the cohort
180 kidney transplant patients who participated in the SPIREN trial
Data and biological material
Data from patient charts (kidney function, albuminuria, blood pressure, concurrent medication, adverse events)